BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 19178612)

  • 1. Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
    Wolber C; Udvardi A; Tatzreiter G; Schneeberger A; Volc-Platzer B
    J Dtsch Dermatol Ges; 2009 May; 7(5):449-52. PubMed ID: 19178612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J; Escudier B; Wechsler J; Spatz A; Robert C
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe sorafenib-induced hand-foot skin reaction.
    Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
    Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
    Hütten M; Lassay L; Sachs B; Deutz P; Mertens R; Baron JM; Merk HF; Ott H
    Pediatr Dermatol; 2009; 26(3):349-50. PubMed ID: 19706105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial granulomatous drug reaction to sorafenib.
    Martínez-Morán C; Nájera L; Ruiz-Casado AI; Romero-Maté A; Espinosa P; Meseguer-Yebra C; Córdoba S; Borbujo JM
    Arch Dermatol; 2011 Sep; 147(9):1118-9. PubMed ID: 21931061
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorafenib-associated hand-foot syndrome in Japanese patients.
    Iijima M; Fukino K; Adachi M; Tsukamoto T; Murai M; Naito S; Minami H; Furuse J; Akaza H
    J Dermatol; 2011 Mar; 38(3):261-6. PubMed ID: 21342228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Palmoplantar cutaneous reaction to sorafenib].
    Echeverría B; Llombart B; Botella-Estrada R; Guillén C
    Actas Dermosifiliogr; 2009 Oct; 100(8):736-7. PubMed ID: 19775561
    [No Abstract]   [Full Text] [Related]  

  • 9. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
    Diamantis ML; Chon SY
    J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient perforating folliculitis induced by sorafenib.
    Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
    J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
    [No Abstract]   [Full Text] [Related]  

  • 11. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B; Kerr H
    Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
    Bednaríková D; Kocák I
    Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hand-foot-syndrome associated with medical tumor therapy - classification and management.
    Degen A; Alter M; Schenck F; Satzger I; Völker B; Kapp A; Gutzmer R
    J Dtsch Dermatol Ges; 2010 Sep; 8(9):652-61. PubMed ID: 20482685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
    Lipworth AD; Robert C; Zhu AX
    Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib: atypical cutaneous side effects.
    Richetta AG; Maiani E; Carboni V; Carlomagno V; Cimillo M; Mattozzi C; Calvieri S
    Eur J Dermatol; 2007; 17(6):549-50. PubMed ID: 17951148
    [No Abstract]   [Full Text] [Related]  

  • 17. Cutaneous drug eruptions induced by sorafenib: a case series.
    Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
    J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hand-foot syndrome and sorafenib].
    Milano G; Mortier L; Digue L; Desmedt E; Ravaud A
    Bull Cancer; 2009 Feb; 96(2):191-7. PubMed ID: 19258226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dermatologic toxicity to sorafenib].
    Velázquez D; de la Cueva P; Zamberk P; Lázaro P
    Actas Dermosifiliogr; 2009; 100(6):518-20. PubMed ID: 19709563
    [No Abstract]   [Full Text] [Related]  

  • 20. Localized dyskeratotic plaque with milia associated with sorafenib.
    Chappell JA; Burkemper NM; Semchyshyn N
    J Drugs Dermatol; 2009 Jun; 8(6):573-6. PubMed ID: 19537383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.